Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Expedited Approval Pathway Coming To China In January

Executive Summary

China Food and Drug Administration is introducing a new priority-review designation pathway that many companies are expected to use, although it is not yet clear just how much time it will save compared with the standard approval process.

Advertisement

Related Content

China Ready For More Medtech Market Access Simplifications
Asia Reg Roundup: Updates From China, Taiwan And Korea
China Seeks Feedback On Priority-Review Designation For Devices

Topics

Advertisement
UsernamePublicRestriction

Register

MT104049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel